# TDP43 A315T Research Report **Protein:** TDP43 A315T **Variant:** A315T **UniProt ID:** Q13148 **Disease Association:** ALS / FTD **Report Generated:** 2026-07-14 00:17 UTC **AlphaFold Confidence (pLDDT):** 64.8% **Structure Folded:** 2026-07-13 --- ## Structure Summary TDP-43 is a protein that normally helps regulate RNA in cells, but when it misfolds and clumps together in neurons, it causes the devastating diseases ALS (which affects muscle control) and frontotemporal dementia (which affects behavior and language). The A315T variant, classified as disease-causing by expert panels and extraordinarily rare in the general population (seen in only 1 in 1.4 million chromosomes), was analyzed using AI-based structure prediction, revealing a moderately confident model (average score 64.8 out of 100) that suggests the mutation likely disrupts the protein's normal structure and promotes the toxic clumping seen in patients' brain cells. --- TDP-43 (TAR DNA-binding protein 43) is an essential RNA-binding protein that normally resides in the cell nucleus where it regulates gene expression, but in ALS and frontotemporal dementia it abnormally accumulates in the cytoplasm (the cell's main compartment) and forms toxic clumps that kill neurons [1]. The A315T mutation, where alanine at position 315 is replaced by threonine, is classified as pathogenic by ClinVar based on evidence from multiple expert submitters and is vanishingly rare in the human population (frequency 6.84e-07), strongly supporting its disease-causing role. This extreme rarity is consistent with severe disease variants that are under strong negative selection pressure. The AlphaFold2 structure prediction for A315T TDP-43 yielded a model with moderate overall confidence (average pLDDT 64.8), indicating substantial uncertainty in the predicted structure. This moderate confidence likely reflects the inherent difficulty in modeling this protein, which contains intrinsically disordered regions that naturally lack stable three-dimensional structure and are prone to forming the pathological aggregates characteristic of ALS and FTD [4]. The threonine substitution at position 315 introduces a polar hydroxyl group where a small nonpolar alanine previously existed, potentially disrupting local protein structure and increasing aggregation propensity. Recent research has illuminated multiple mechanisms by which TDP-43 dysfunction drives neurodegeneration. Studies show that TDP-43 pathology is associated with accumulation of genomic damage in neurons, suggesting that loss of normal TDP-43 function may compromise DNA repair processes [1]. The protein's tendency to undergo liquid-to-solid phase transitions—shifting from functional liquid droplets to toxic solid aggregates—appears to be modulated by nuclear export mechanisms, and mutations may accelerate this pathological transition [4]. Additionally, TDP-43 aggregation is linked to oxidative stress and can interact with other ALS-related proteins, creating a cascade of cellular dysfunction [2][3]. Given the moderate confidence of this structural model, interpretations must remain cautious. The predicted structure may not accurately represent local conformational changes around position 315, and experimental validation would be essential to confirm specific structural alterations. However, the pathogenic classification, extreme rarity, and chemical nature of the A315T substitution collectively support the hypothesis that this variant destabilizes TDP-43, promoting the cytoplasmic mislocalization and aggregation that characterize ALS and FTD pathology. The development of biomarkers to distinguish TDP-43 pathology from other neurodegenerative processes continues to advance clinical research [5], offering hope for more targeted therapeutic strategies for patients carrying pathogenic variants like A315T. ## Works Cited [1] Zhou et al. (2026). Recurrent patterns of TOP1-mediated neuronal genomic damage shared by major neurodegenerative disorders. Cell. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42385702/) [2] Chen et al. (2026). TRIM16 attenuates TDP43-mediated oxidative injury by coordinating Nrf2 activation and TFR1 autophagic degradation. Free radical biology & medicine. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42092406/) [3] Ribeiro et al. (2026). Molecular Modulation of the Crosstalk Between TDP-43 and SOD1. International journal of molecular sciences. [PubMed](https://pubmed.ncbi.nlm.nih.gov/42074053/) [4] Chin et al. (2026). Nuclear export modulates TDP-43 phase transition and cytoplasmic aggregation. bioRxiv : the preprint server for biology. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41993496/) [5] Honey et al. (2026). An acetylated Tau-174 CSF biomarker discriminates between TDP-43 and tau pathology in patients with frontotemporal lobar degeneration. Nature medicine. [PubMed](https://pubmed.ncbi.nlm.nih.gov/41986736/) ## Similar Research **Integrative genetic analysis illuminates ALS heritability and identifies risk genes.** Megat et al. (2023) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/36670122/) **Biomarker discovery in Alzheimer's and neurodegenerative diseases using Nucleic Acid Linked Immuno-Sandwich Assay.** Ashton et al. (2025) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/40401628/) **Frontotemporal dementia. How to deal with its diagnostic complexity?** Antonioni et al. (2025) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/39911129/) **Proteomic analysis reveals distinct cerebrospinal fluid signatures across genetic frontotemporal dementia subtypes.** Sogorb-Esteve et al. (2025) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/39908349/) **MATR3 pathogenic variants differentially impair its cryptic splicing repression function.** Khan et al. (2024) *Related research* [Read on PubMed](https://pubmed.ncbi.nlm.nih.gov/38320753/) --- ## Open Targets Disease Associations | Disease | Score | Data Sources | |---------|-------|--------------| | amyotrophic lateral sclerosis | 0.820 | literature, animal_model, genetic_association, genetic_literature | | frontotemporal dementia with motor neuron disease | 0.707 | literature, animal_model, genetic_association, genetic_literature | | familial amyotrophic lateral sclerosis | 0.480 | literature, animal_model, genetic_literature | | frontotemporal dementia | 0.453 | literature, animal_model, genetic_association, genetic_literature | | neurodegenerative disease | 0.453 | literature, affected_pathway | | motor neuron disorder | 0.446 | literature, genetic_association | | amyotrophic lateral sclerosis, dominant | 0.370 | genetic_literature | | hereditary disease | 0.191 | literature, genetic_association | | immunodeficiency due to MASP-2 deficiency | 0.188 | genetic_association | | Parkinson disease | 0.147 | literature, animal_model, genetic_association | *...and 2568 more associations* --- ## AI Research Brief # Research Brief: TDP-43 A315T Variant ## Pathogenic Mechanisms The A315T variant in TAR DNA-binding protein 43 (TDP-43) affects a residue within the C-terminal glycine-rich domain, which is critical for protein-protein interactions and regulation of TDP-43 function. TDP-43 normally functions as a DNA/RNA-binding protein involved in transcriptional regulation, RNA splicing, and mRNA stability modulation, with key roles in 3'-UTR-mediated mRNA stabilization and destabilization. The A315T mutation disrupts this delicate regulatory balance, potentially affecting interactions with known binding partners including FUS, ELAVL1, and PPP1R15A. A critical pathogenic mechanism involves enhanced propensity for amyloid fibril formation, a biological process in which TDP-43 is inherently involved but which becomes aberrantly enhanced by disease-associated mutations. The variant may alter the normal liquid-liquid phase separation properties of TDP-43, leading to pathological aggregation. While the primary aggregation hotspot identified lies at residues 228-232 (score: 0.71) upstream of the A315T site, this mutation likely influences the overall conformational landscape that promotes protein misfolding and cytoplasmic accumulation, the hallmark pathological feature of TDP-43 proteinopathies. ## Clinical Significance The A315T variant represents one of several C-terminal domain mutations in TDP-43 associated with familial amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). Mutations in this region are clinically significant as they cause dominant hereditary disease with variable penetrance and phenotypic expression. The C-terminal domain is a mutation hotspot, with variants in this region consistently demonstrating pathogenic potential through loss of normal function combined with toxic gain-of-function mechanisms. Functionally, the A315T substitution introduces a polar threonine residue in place of the small, hydrophobic alanine, potentially disrupting local protein structure and affecting the identical protein binding capacity essential for TDP-43's normal homodimerization and stress granule dynamics. ## Therapeutic Landscape The therapeutic landscape for TDP-43 proteinopathies remains challenging, with aggregation prevention representing a key target area. The identified aggregation hotspot at residues 228-232 (score: 0.71) provides a rational target for peptide-based inhibition strategies, though specific validated peptide inhibitors for this region are not currently documented in the available data. The structural understanding of TDP-43 aggregation mechanisms suggests that therapeutics should focus on preventing the transition from normal physiological condensates to pathological aggregates. Strategies might include small molecules or peptides that stabilize the native state, prevent aberrant protein-protein interactions, or enhance clearance of misfolded species. The known interactome, including stress granule-associated proteins like FUS and ELAVL1, provides additional potential intervention points for modulating TDP-43 pathology. ## Research Directions Critical knowledge gaps remain regarding the precise molecular mechanisms by which the A315T variant promotes pathological aggregation and whether this occurs through cell-autonomous or non-cell-autonomous mechanisms. Priority research directions include: (1) high-resolution structural studies of the C-terminal domain bearing the A315T mutation to understand conformational changes; (2) investigation of how this variant affects phase separation dynamics and stress granule formation under cellular stress; (3) screening for peptide or small molecule inhibitors targeting the 228-232 aggregation hotspot; (4) characterization of variant effects on interactions with RNA targets and protein partners like PPP1R15A in stress response pathways; and (5) development of biomarkers for early detection of TDP-43 pathology in A315T carriers. Understanding genotype-phenotype correlations and penetrance modifiers would inform genetic counseling and identify potential therapeutic windows for intervention. --- ## Agent Findings ### Literature (1) - **2026-07-13:** None of these papers are directly relevant to the TDP-43 A315T variant. While several papers discuss TDP-43 pathology generally in ALS/FTD contexts and one mentions TARDBP mutations broadly (PMID 40981770), none specifically investigate, characterize, or mention the A315T variant that is the focus of this query. ### Clinical (1) - **2026-07-13:** --- *Generated by [Clarity Protocol](https://clarityprotocol.io)* **Data Sources:** - Structure predictions: AlphaFold via ColabFold - Clinical variant data: ClinVar, gnomAD - Disease associations: Open Targets Platform - Research findings: AI agents (PubMed, clinical databases)